METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS Russian patent published in 2024 - IPC A61K31/137 A61P35/00 A61P35/04 

FIELD: medicine.

SUBSTANCE: invention relates to oncology. Disclosed is use of elacestrant or a pharmaceutically acceptable salt thereof in a method of inhibiting and destroying the receptor-negative human epidermal growth factor-2 and the mutant oestrogen receptor-positive breast cancer in the subject, wherein said individual is pre-treated with tamoxifen, an aromatase inhibitor and fulvestrant. Mutated oestrogen receptor alpha-positive breast cancer contains one or more mutations selected from a group consisting of D538G, Y537X1, L536X2, P535H, V534E, S463P, V392I, E380Q and combinations thereof, wherein X₁ is S, N or C; and X₂ is R or Q.

EFFECT: invention provides treating breast cancer which is resistant to anti-oestrogen agents, aromatase inhibitors or combinations thereof.

18 cl, 10 dwg, 1 ex